> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Personalized Drug Development is Faster: Study
- URL: https://www.fdaweb.com/personalized-drug-development-is-faster-study/
- Published: 2016-07-28T12:00:00.000Z
- Updated: 2026-09-14T21:18:58.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5136335

A review of cancer drugs approved by FDA between 1998 and 2014 found that a personalized approach for drug development was associated with faster clinical development, according to an online study [report](http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=10588&path%5B%5D=33452&ref=fdaweb.com) in *Impact Journals*. Researchers also reported no differences in access to FDA expedited review programs between personalized and non-personalized drugs.

The study says that one of the biggest oncology challenges is to deliver more efficient and safer drugs in a shorter time frame to patients with cancer. The review showed, the researchers say, that drugs developed under a biomarker-based strategy (also known as personalized or precision oncology) were associated with a significantly shorter clinical phase of development (a median of 58.5 months compared with 93.5 months for non-personalized drugs).

“Targeted drugs that were developed for a molecularly selected population had some of the shortest clinical development timelines,” the report says. “Aiming to obtain a large difference in a small patient group was an important driver of their success. It is possible that a higher clinical activity of biomarker driven drugs … could also explain their faster clinical development. It is also interesting to note that we could not detect differences in total approval time if the drug approval was based on a randomized or non-randomized trial.”